Last reviewed · How we verify

Seqirus — Portfolio Competitive Intelligence Brief

Seqirus pipeline: 4 marketed, 0 filed, 16 Phase 3, 22 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 16 Phase 3 22 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
CSL Influenza Vaccine CSL Influenza Vaccine marketed inactivated influenza vaccine Immunology
Enzira® vaccine Enzira® vaccine marketed Inactivated influenza vaccine Immunology / Infectious Disease
CSL Limited Influenza Vaccine CSL Limited Influenza Vaccine marketed inactivated influenza vaccine Immunology
CSL Limited Influenza Virus Vaccine CSL Limited Influenza Virus Vaccine marketed inactivated influenza vaccine Immunology / Infectious Disease
Comparator QIV Comparator QIV phase 3 Inactivated influenza vaccine Immunology / Infectious Disease
Investigational aQIVc Investigational aQIVc phase 3 Influenza vaccine (quadrivalent, cell-based) Immunology / Infectious Disease
Novartis Investigational H5N1 vaccine Novartis Investigational H5N1 vaccine phase 3 Vaccine Immunology / Infectious Disease
Seqirus QIV Seqirus QIV phase 3 inactivated vaccine Infectious Disease
QIV or TIV QIV or TIV phase 3 Influenza vaccine Infectious disease
Adjuvanted QIV (aQIV) Adjuvanted QIV (aQIV) phase 3 Vaccine Immunology
licensed QIVr licensed QIVr phase 3 vaccine Infectious Disease
Novartis Seasonal Influenza Vaccine Novartis Seasonal Influenza Vaccine phase 3 vaccine Infectious Diseases

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Sanofi Pasteur, a Sanofi Company · 6 shared drug classes
  2. GlaxoSmithKline · 5 shared drug classes
  3. Sinovac Biotech Co., Ltd · 5 shared drug classes
  4. Sanofi · 3 shared drug classes
  5. National Institute of Allergy and Infectious Diseases (NIAID) · 3 shared drug classes
  6. Il-Yang Pharm. Co., Ltd. · 3 shared drug classes
  7. Merck Sharp & Dohme LLC · 3 shared drug classes
  8. Novartis · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Seqirus:

Cite this brief

Drug Landscape (2026). Seqirus — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/seqirus. Accessed 2026-05-13.

Related